LYDON PHARMACY GROUP LTD.

Company Registration Number:
03986971 (England and Wales)

Unaudited abridged accounts for the year ended 31 August 2025

Period of accounts

Start date: 01 January 2025

End date: 31 August 2025

LYDON PHARMACY GROUP LTD.

Contents of the Financial Statements

for the Period Ended 31 August 2025

Balance sheet
Notes

LYDON PHARMACY GROUP LTD.

Balance sheet

As at 31 August 2025


Notes
8 months to 31 August 2025
2024


£
£
Fixed assets
Tangible assets: 3 359,303 318,031
Total fixed assets: 359,303 318,031
Current assets
Stocks: 83,355 130,714
Debtors:   302,154 596,684
Cash at bank and in hand: 679 73,732
Total current assets: 386,188 801,130
Creditors: amounts falling due within one year:   (538,555) (567,691)
Net current assets (liabilities): (152,367) 233,439
Total assets less current liabilities: 206,936 551,470
Creditors: amounts falling due after more than one year:     (130,551)
Provision for liabilities: (40,947) (54,297)
Total net assets (liabilities): 165,989 366,622
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: 164,989 365,622
Shareholders funds: 165,989 366,622

The notes form part of these financial statements

LYDON PHARMACY GROUP LTD.

Balance sheet statements

For the year ending 31 August 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 27 May 2026
and signed on behalf of the board by:

Name: Mr S Kanaparthy
Status: Director

The notes form part of these financial statements

LYDON PHARMACY GROUP LTD.

Notes to the Financial Statements

for the Period Ended 31 August 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LYDON PHARMACY GROUP LTD.

Notes to the Financial Statements

for the Period Ended 31 August 2025

2. Employees

8 months to 31 August 2025 2024
Average number of employees during the period 31 31

LYDON PHARMACY GROUP LTD.

Notes to the Financial Statements

for the Period Ended 31 August 2025

3. Tangible Assets

Total
Cost £
At 01 January 2025 743,782
Additions 56,246
At 31 August 2025 800,028
Depreciation
At 01 January 2025 425,751
Charge for year 14,974
At 31 August 2025 440,725
Net book value
At 31 August 2025 359,303
At 31 December 2024 318,031